Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines.

Engelsgjerd S, Kunnimalaiyaan S, Kandil E, Gamblin TC, Kunnimalaiyaan M.

PLoS One. 2019 Mar 14;14(3):e0213776. doi: 10.1371/journal.pone.0213776. eCollection 2019.

2.

Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.

Kunnimalaiyaan S, Schwartz VK, Jackson IA, Clark Gamblin T, Kunnimalaiyaan M.

BMC Cancer. 2018 May 11;18(1):560. doi: 10.1186/s12885-018-4474-7.

3.

Antiproliferative and apoptotic effects of xanthohumol in cholangiocarcinoma.

Walden D, Kunnimalaiyaan S, Sokolowski K, Clark TG, Kunnimalaiyaan M.

Oncotarget. 2017 Sep 30;8(50):88069-88078. doi: 10.18632/oncotarget.21422. eCollection 2017 Oct 20.

4.

Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines.

Kunnimalaiyaan S, Sokolowski K, Gamblin TC, Kunnimalaiyaan M.

Am J Surg. 2017 Apr;213(4):645-651. doi: 10.1016/j.amjsurg.2016.12.001. Epub 2016 Dec 11.

PMID:
28007318
5.

Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy.

Sokolowski KM, Balamurugan M, Kunnimalaiyaan S, Wilson J, Gamblin TC, Kunnimalaiyaan M.

Am J Surg. 2016 Apr;211(4):755-60. doi: 10.1016/j.amjsurg.2015.11.029. Epub 2016 Jan 6.

PMID:
26850133
6.

Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer.

Sokolowski KM, Koprowski S, Kunnimalaiyaan S, Balamurugan M, Gamblin TC, Kunnimalaiyaan M.

Anticancer Agents Med Chem. 2016;16(1):29-37. Review.

PMID:
26179270
7.

Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression.

Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M.

HPB (Oxford). 2015 Sep;17(9):770-6. doi: 10.1111/hpb.12442. Epub 2015 Jul 6.

8.

Xanthohumol inhibits Notch signaling and induces apoptosis in hepatocellular carcinoma.

Kunnimalaiyaan S, Sokolowski KM, Balamurugan M, Gamblin TC, Kunnimalaiyaan M.

PLoS One. 2015 May 26;10(5):e0127464. doi: 10.1371/journal.pone.0127464. eCollection 2015.

9.

Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma.

Koprowski S, Sokolowski K, Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M.

J Surg Res. 2015 Oct;198(2):434-40. doi: 10.1016/j.jss.2015.03.029. Epub 2015 Mar 19. Review.

PMID:
25890434
10.

Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells.

Kunnimalaiyaan S, Trevino J, Tsai S, Gamblin TC, Kunnimalaiyaan M.

Mol Cancer Ther. 2015 Jun;14(6):1395-403. doi: 10.1158/1535-7163.MCT-14-0915. Epub 2015 Apr 17.

11.

Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis.

Wilson JM, Kunnimalaiyaan S, Kunnimalaiyaan M, Gamblin TC.

Cancer Cell Int. 2015 Feb 4;15(1):13. doi: 10.1186/s12935-015-0161-9. eCollection 2015.

12.

MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest.

Wilson JM, Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M.

J Surg Res. 2014 Oct;191(2):280-5. doi: 10.1016/j.jss.2014.05.083. Epub 2014 Jun 4.

PMID:
24996256
13.

Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.

Carter YM, Kunnimalaiyaan S, Chen H, Gamblin TC, Kunnimalaiyaan M.

Cancer Biol Ther. 2014 May;15(5):510-5. doi: 10.4161/cbt.28015. Epub 2014 Feb 12.

14.

MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition.

Burke JF, Schlosser L, Harrison AD, Kunnimalaiyaan M, Chen H.

Ann Surg Oncol. 2013 Nov;20(12):3862-8. doi: 10.1245/s10434-013-3168-2. Epub 2013 Jul 31.

15.

Mitochondria-targeted antioxidant and glycolysis inhibition: synergistic therapy in hepatocellular carcinoma.

Dilip A, Cheng G, Joseph J, Kunnimalaiyaan S, Kalyanaraman B, Kunnimalaiyaan M, Gamblin TC.

Anticancer Drugs. 2013 Oct;24(9):881-8. doi: 10.1097/CAD.0b013e32836442c6.

16.

Leflunomide suppresses growth in human medullary thyroid cancer cells.

Alhefdhi A, Burke JF, Redlich A, Kunnimalaiyaan M, Chen H.

J Surg Res. 2013 Nov;185(1):212-6. doi: 10.1016/j.jss.2013.05.089. Epub 2013 Jun 19.

17.

Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth.

Yu XM, Jaskula-Sztul R, Ahmed K, Harrison AD, Kunnimalaiyaan M, Chen H.

Mol Cancer Ther. 2013 Jul;12(7):1276-87. doi: 10.1158/1535-7163.MCT-12-0841. Epub 2013 Apr 17.

18.

Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.

Somnay Y, Simon K, Harrison AD, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M.

Anticancer Drugs. 2013 Jan;24(1):66-72. doi: 10.1097/CAD.0b013e3283584f75. Erratum in: Anticancer Drugs. 2013 Jul;24(6):658.

19.

Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.

Xiao Y, Jaskula-Sztul R, Javadi A, Xu W, Eide J, Dammalapati A, Kunnimalaiyaan M, Chen H, Gong S.

Nanoscale. 2012 Nov 21;4(22):7185-93. doi: 10.1039/c2nr31853a.

20.

Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.

Somnay Y, Chen H, Kunnimalaiyaan M.

Neuroendocrinology. 2013;97(2):183-92. doi: 10.1159/000341810. Epub 2012 Sep 4.

21.

The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors.

Somnay YR, Kunnimalaiyaan M.

Glob J Biochem. 2012;3. pii: 3. Epub 2011 Mar 8. Review.

22.

Antiproliferative effect of chrysin on anaplastic thyroid cancer.

Phan T, Yu XM, Kunnimalaiyaan M, Chen H.

J Surg Res. 2011 Sep;170(1):84-8. doi: 10.1016/j.jss.2011.03.064. Epub 2011 Apr 20.

23.

Expression of the active Notch1 decreases MTC tumor growth in vivo.

Jaskula-Sztul R, Pisarnturakit P, Landowski M, Chen H, Kunnimalaiyaan M.

J Surg Res. 2011 Nov;171(1):23-7. doi: 10.1016/j.jss.2011.03.035. Epub 2011 Apr 13.

24.

Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method.

Pinchot SN, Jaskula-Sztul R, Ning L, Peters NR, Cook MR, Kunnimalaiyaan M, Chen H.

Cancer. 2011 Apr 1;117(7):1386-98. doi: 10.1002/cncr.25652. Epub 2010 Nov 8.

25.

A preclinical and clinical study of lithium in low-grade neuroendocrine tumors.

Lubner SJ, Kunnimalaiyaan M, Holen KD, Ning L, Ndiaye M, Loconte NK, Mulkerin DL, Schelman WR, Chen H.

Oncologist. 2011;16(4):452-7. doi: 10.1634/theoncologist.2010-0323. Epub 2011 Mar 10.

26.

Hesperetin, a potential therapy for carcinoid cancer.

Zarebczan B, Pinchot SN, Kunnimalaiyaan M, Chen H.

Am J Surg. 2011 Mar;201(3):329-32; discussion 333. doi: 10.1016/j.amjsurg.2010.08.018.

27.

Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.

Truong M, Cook MR, Pinchot SN, Kunnimalaiyaan M, Chen H.

Ann Surg Oncol. 2011 May;18(5):1506-11. doi: 10.1245/s10434-010-1488-z. Epub 2010 Dec 24.

28.

MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.

Meyer-Rochow GY, Jackson NE, Conaglen JV, Whittle DE, Kunnimalaiyaan M, Chen H, Westin G, Sandgren J, Stålberg P, Khanafshar E, Shibru D, Duh QY, Clark OH, Kebebew E, Gill AJ, Clifton-Bligh R, Robinson BG, Benn DE, Sidhu SB.

Endocr Relat Cancer. 2010 Aug 16;17(3):835-46. doi: 10.1677/ERC-10-0142. Print 2010 Sep.

PMID:
20621999
29.

Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids.

Alexander VM, Roy M, Steffens KA, Kunnimalaiyaan M, Chen H.

Int J Clin Exp Med. 2010 Mar 28;3(2):95-102.

30.

Lithium inhibits carcinoid cell growth in vitro.

Greenblatt DY, Ndiaye M, Chen H, Kunnimalaiyaan M.

Am J Transl Res. 2010 May 10;2(3):248-53.

31.

Focal adhesion kinase, a downstream mediator of Raf-1 signaling, suppresses cellular adhesion, migration, and neuroendocrine markers in BON carcinoid cells.

Ning L, Chen H, Kunnimalaiyaan M.

Mol Cancer Res. 2010 May;8(5):775-82. doi: 10.1158/1541-7786.MCR-09-0525. Epub 2010 Apr 20.

32.

Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer.

Cook MR, Luo J, Ndiaye M, Chen H, Kunnimalaiyaan M.

Am J Surg. 2010 Mar;199(3):315-8; discussion 318. doi: 10.1016/j.amjsurg.2009.08.034.

33.

Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth.

Cook MR, Pinchot SN, Jaskula-Sztul R, Luo J, Kunnimalaiyaan M, Chen H.

Mol Cancer Ther. 2010 Feb;9(2):429-37. doi: 10.1158/1535-7163.MCT-09-0718. Epub 2010 Jan 26.

34.

Medullary thyroid carcinoma: targeted therapies and future directions.

Pinchot SN, Kunnimalaiyaan M, Sippel RS, Chen H.

J Oncol. 2009;2009:183031. doi: 10.1155/2009/183031. Epub 2009 Dec 24.

35.

Notch 1 signaling is active in ovarian cancer.

Rose SL, Kunnimalaiyaan M, Drenzek J, Seiler N.

Gynecol Oncol. 2010 Apr;117(1):130-3. doi: 10.1016/j.ygyno.2009.12.003. Epub 2010 Jan 8.

PMID:
20060575
36.

ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines.

Deming D, Geiger P, Chen H, Kunnimalaiyaan M, Holen K.

J Surg Res. 2010 Jun 1;161(1):28-32. doi: 10.1016/j.jss.2009.06.013. Epub 2009 Jul 12.

37.

AKT and PTEN expression in human gastrointestinal carcinoid tumors.

Pitt SC, Davis R, Kunnimalaiyaan M, Chen H.

Am J Transl Res. 2009 Feb 28;1(3):291-9.

38.

MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype.

Chen JY, Cook MR, Pinchot SN, Kunnimalaiyaan M, Chen H.

J Surg Res. 2010 Jan;158(1):15-9. doi: 10.1016/j.jss.2009.05.032.

39.

Inhibition of the PI3K pathway suppresses hormonal secretion and limits growth in pheochromocytoma cells.

Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H.

World J Surg. 2009 Nov;33(11):2452-7. doi: 10.1007/s00268-009-0175-3.

40.

Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.

Pitt SC, Chen H, Kunnimalaiyaan M.

J Am Coll Surg. 2009 Jul;209(1):82-8. doi: 10.1016/j.jamcollsurg.2009.03.006. Epub 2009 May 1.

41.

Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors.

Pitt SC, Chen H, Kunnimalaiyaan M.

Ann Surg Oncol. 2009 Oct;16(10):2936-42. doi: 10.1245/s10434-009-0591-5. Epub 2009 Jul 9.

42.

Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies.

Goodell CA, Belisle JA, Gubbels JA, Migneault M, Rancourt C, Connor J, Kunnimalaiyaan M, Kravitz R, Tucker W, Zwick M, Patankar MS.

J Ovarian Res. 2009 Jun 18;2(1):8. doi: 10.1186/1757-2215-2-8.

43.

Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.

Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H.

J Surg Res. 2010 Apr;159(2):640-4. doi: 10.1016/j.jss.2008.08.004. Epub 2008 Sep 4.

44.

Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta.

Adler JT, Cook M, Luo Y, Pitt SC, Ju J, Li W, Shen B, Kunnimalaiyaan M, Chen H.

Mol Cancer Ther. 2009 Apr;8(4):914-20. doi: 10.1158/1535-7163.MCT-08-0712. Erratum in: Mol Cancer Ther. 2010 May;9(5):1482.

45.

Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway.

Pinchot SN, Adler JT, Luo Y, Ju J, Li W, Shen B, Kunnimalaiyaan M, Chen H.

Am J Surg. 2009 Mar;197(3):313-9. doi: 10.1016/j.amjsurg.2008.10.007.

46.

Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells.

Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H.

Surgery. 2008 Dec;144(6):956-61; discussion 961-2. doi: 10.1016/j.surg.2008.08.027.

47.

Regulation of cell-cell contact molecules and the metastatic phenotype of medullary thyroid carcinoma by the Raf-1/MEK/ERK pathway.

Ning L, Kunnimalaiyaan M, Chen H.

Surgery. 2008 Dec;144(6):920-4; discussion 924-5. doi: 10.1016/j.surg.2008.07.020.

48.

Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors.

Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H.

Ann Surg Oncol. 2009 Feb;16(2):481-6. doi: 10.1245/s10434-008-0194-6. Epub 2008 Nov 22.

49.

Valproic acid induces Notch1 signaling in small cell lung cancer cells.

Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H.

J Surg Res. 2008 Jul;148(1):31-7. doi: 10.1016/j.jss.2008.03.008. Epub 2008 Apr 10.

50.

Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.

Ning L, Jaskula-Sztul R, Kunnimalaiyaan M, Chen H.

Ann Surg Oncol. 2008 Sep;15(9):2600-5. doi: 10.1245/s10434-008-0006-z. Epub 2008 Jun 18.

Supplemental Content

Loading ...
Support Center